目的 探讨痰热清注射液联合复方二氯醋酸二异丙胺注射液治疗胆汁淤积性肝病的临床疗效。方法 选取2016年1月—2017年6月乐山市人民医院收治的胆汁淤积性肝病患者96例为研究对象，采取随机数字表法将患者分为对照组和治疗组，每组各48例。对照组静脉滴注复方二氯醋酸二异丙胺注射液，80 mg加入5%葡萄糖液250 mL中，1次/d。治疗组在对照组基础上静脉滴注痰热清注射液，20 mL加入5%葡萄糖注射液250 mL中，1次/d。两组患者均连续治疗1个月。观察两组的临床疗效，比较两组肝功能指标、肝纤维化指标和黄疸消退情况。结果 治疗后，对照组和治疗组的总有效率分别为91.67%、100.00%，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组血清总胆红素（TBiL）、结合胆红素（DBiL）、γ-谷氨酰转移酶（GGT）、碱性磷酸酶（ALP）、丙氨酸氨基转移酶（ALT）水平均显著下降，同组治疗前后比较差异具有统计学意义（P < 0.05）；且治疗组这些肝功能指标明显低于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组透明质酸（HA）、层黏连蛋白（LN）、Ⅲ型前胶原（PCⅢ）、Ⅳ型胶原（Ⅳ-C）水平均显著下降，同组治疗前后比较差异具有统计学意义（P < 0.05）；且治疗组这些肝纤维化指标明显低于对照组，两组比较差异具具有统计学意义（P < 0.05）。治疗10、20、30 d后，治疗组黄疸消退情况明显优于对照组，两组比较差异具有统计学意义（P < 0.05）。结论 痰热清注射液联合复方二氯醋酸二异丙胺注射液治疗胆汁淤积性肝病具有较好的临床疗效，可改善肝功能和肝纤维化，有利于黄疸消退，安全性较好，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Tanreqing Injection combined with Compound Diisopropylamine Dichloroacetate Injection in treatment of cholestasis liver disease. Methods Patients (96 cases) with cholestasis liver disease in the People's Hospital of Leshan from January 2016 to June 2017 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were iv administered with Compound Diisopropylamine Dichloroacetate Injection, 80 mg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were iv administered with Tanreqing Injection on the basis of the control group, 20 mL added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and liver function indexes, liver fibrosis indexes, and jaundice regression in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 91.67% and 100.00%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of TBiL, DBiL, GGT, ALP, and ALT in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the liver function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of HA, LN, PCⅢ, and Ⅳ-C in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the liver fibrosis indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment for 10, 20, and 30 d, the jaundice regression in the treatment group was significantly better than that in the control group, and there was difference between two groups (P < 0.05). Conclusion Tanreqing Injection combined with Compound Diisopropylamine Dichloroacetate Injection has clinical curative effect in treatment of cholestasis liver disease, can improve live function and liver fibrosis, conducive to jaundice regression, with good safety, which has a certain clinical application value.